R 
Resmed RMD · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
235.74
+0.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$5.65bn
FY2017FY2026
Net income
$1.52bn
FY2017FY2026
Free cash flow
$1.65bn
FY2017FY2026
Shareholders' equity
$6.59bn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65bn | $5.15bn | $4.69bn | $4.22bn | $3.58bn | $3.20bn | $2.96bn | $2.61bn | $2.34bn | $2.07bn |
| Gross profit | $3.46bn | $3.05bn | $2.66bn | $2.36bn | $2.02bn | $1.84bn | $1.72bn | $1.54bn | $1.36bn | $1.20bn |
| Research and development | $378.3m | $331.3m | $307.5m | $287.6m | $253.6m | $225.3m | $201.9m | $180.7m | $155.1m | $144.5m |
| Operating income | $1.89bn | $1.69bn | $1.32bn | $1.13bn | $982.8m | $903.7m | $809.7m | $579.3m | $541.8m | $425.8m |
| Net income | $1.52bn | $1.40bn | $1.02bn | $897.6m | $779.4m | $474.5m | $621.7m | $404.6m | $315.6m | $342.3m |
| Diluted earnings per share | 10.51 | 9.53 | 6.92 | 6.08 | 5.29 | 3.23 | 4.25 | 2.78 | 2.19 | 2.38 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.97bn | $8.17bn | $6.87bn | $6.75bn | $5.10bn | $4.73bn | $4.59bn | $4.11bn | $3.06bn | $3.47bn |
| Cash and short-term investments | $1.47bn | $1.21bn | $238.4m | $227.9m | $273.7m | $295.3m | $463.2m | $147.1m | $188.7m | $821.9m |
| Total liabilities | $2.38bn | $2.21bn | $2.01bn | $2.62bn | $1.74bn | $1.84bn | $2.09bn | $2.04bn | $1.00bn | $1.51bn |
| Debt | $289.1m | $668.3m | $707.2m | $1.44bn | $775.2m | $655.4m | $1.18bn | $1.27bn | $281.5m | $1.08bn |
| Shareholders' equity | $6.59bn | $5.97bn | $4.86bn | $4.13bn | $3.36bn | $2.89bn | $2.50bn | $2.07bn | $2.06bn | $1.96bn |
| Shares outstanding | 145m | 147m | 148m | 148m | 147m | 147m | 146m | 146m | 144m | 144m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $1.81bn | $1.75bn | $1.40bn | $693.3m | $351.1m | $736.7m | $802.3m | $459.1m | $505.0m | $414.1m |
| Capital spending | −$156.3m | −$89.9m | −$114.9m | −$134.0m | −$156.0m | −$116.8m | −$105.9m | −$77.3m | −$71.5m | −$71.5m |
| Free cash flow | $1.65bn | $1.66bn | $1.29bn | $559.3m | $195.1m | $619.9m | $696.3m | $381.7m | $433.6m | $342.6m |
| Dividends paid | −$349.7m | −$310.9m | −$282.3m | −$258.3m | −$245.3m | −$226.7m | −$225.1m | −$211.7m | −$199.5m | −$186.3m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46bn | $1.43bn | $1.42bn | $1.34bn | $1.35bn | $1.29bn | $1.28bn | $1.22bn |
| Gross profit | $861.2m | $891.0m | $884.7m | $820.8m | $820.1m | $766.4m | $751.3m | $717.2m |
| Operating income | $448.7m | $499.8m | $497.6m | $446.5m | $454.5m | $426.3m | $418.0m | $387.3m |
| Net income | $383.4m | $398.7m | $392.6m | $348.5m | $379.7m | $365.0m | $344.6m | $311.4m |
| Diluted earnings per share | 2.64 | 2.75 | 2.67 | 2.37 | 2.58 | 2.48 | 2.33 | 2.11 |
| Cash from operations | $1.80bn | $554.0m | $339.0m | $457.0m | $538.0m | $578.0m | $308.0m | $325.0m |
| Capital spending | −$156.0m | −$33.0m | −$34.0m | −$42.0m | −$30.0m | −$23.0m | −$18.0m | −$19.0m |
| Free cash flow | $1.65bn | $521.0m | $305.0m | $415.0m | $508.0m | $555.0m | $290.0m | $306.0m |
| Total assets | $8.97bn | $8.78bn | $8.50bn | $8.31bn | $8.17bn | $7.57bn | $7.14bn | $7.22bn |
| Cash and short-term investments | $1.47bn | $1.66bn | $1.43bn | $1.38bn | $1.21bn | $944.8m | $521.9m | $426.4m |
| Debt | $289.1m | $693.3m | $693.6m | $698.5m | $698.8m | $701.8m | $700.6m | $705.8m |
| Shareholders' equity | $6.59bn | $6.49bn | $6.32bn | $6.12bn | $5.97bn | $5.55bn | $5.25bn | $5.20bn |
Financial ratios
Data as of 20 Sept 2026
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 61.2% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% |
| Operating margin | 33.5% | 32.7% | 28.2% | 26.8% | 27.5% | 28.3% |
| Net margin | 26.9% | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% |
| Return on equity | 23.1% | 23.5% | 21.0% | 21.7% | 23.2% | 16.4% |
| Return on assets | 17.0% | 17.1% | 14.9% | 13.3% | 15.3% | 10.0% |
| Free cash flow yield | 6.0% | 5.5% | 4.5% | 2.5% | 1.5% | 2.6% |
| Revenue growth | 9.9% | 9.8% | 10.9% | 18.0% | 11.9% | 8.1% |
| Earnings growth | 8.8% | 37.2% | 13.7% | 15.2% | 64.3% | -23.7% |
| Current ratio | 3.10x | 3.44x | 2.59x | 3.12x | 2.80x | 1.73x |
| Debt to equity | 0.10x | 0.12x | 0.15x | 0.35x | 0.24x | 0.24x |
| Equity ratio | 73.4% | 73.0% | 70.8% | 61.2% | 66.0% | 61.0% |
| Interest coverage | 65.20x | 133.66x | 28.88x | 23.89x | 44.05x | 37.67x |
| R&D as a share of sales | 6.7% | 6.4% | 6.6% | 6.8% | 7.1% | 7.0% |
| Buybacks as a share of market value | 1.4% | 0.4% | -0.0% | -0.1% | -0.2% | -0.4% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 10.2% | 12.1% | 11.9% |
| Operating income | 18.7% | 15.9% | 16.0% |
| Net income | 19.3% | 26.3% | 15.8% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 60.3% | 58.5% | 58.1% | 58.2% |
| Operating margin | 33.1% | 30.6% | 29.9% | 27.9% |
| Net margin | 27.1% | 24.6% | 23.0% | 21.2% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 22.9 | 25.3 | 33.1 | 28.3 | 39.4 | 80.7 | 50.1 | 55.8 | 52.1 | 35.6 |
| Price to sales | 6.2 | 6.9 | 7.2 | 6.0 | 8.6 | 12.0 | 10.5 | 8.7 | 7.0 | 5.9 |
Market value over time
31 Oct 2016 to 18 Sept 2026, in USD
$8.49bn$32.62bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 5% | 33% | -17% | -16% | 16% | 37% | 45% | 26% | 38% | 19% |
Dividends and splits
Per share, in the currency the company pays
Paid for 14 years. Last went ex-dividend on 20 Aug 2026.
| FY2027 | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.66 | 2.40 | 2.12 | 1.92 | 1.76 | 1.68 | 1.56 | 1.56 |
- 2-for-1 split · 31 Aug 2010
- 2-for-1 split · 3 Oct 2005
- 2-for-1 split · 3 Apr 2000
- 2-for-1 split · 17 Nov 1998
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.